For information, the company have announced that the CM73L trial did not meet its primary endpoint and therefore they will no longer be pursuing a Marketing Authorisation Application in this indication. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes.
 
Status Suspended
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6248

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
16 May 2024 Suspended. For information, the company have announced that the CM73L trial did not meet its primary endpoint and therefore they will no longer be pursuing a Marketing Authorisation Application in this indication. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes.
16 May 2024 Appraisal suspended.
05 October 2023 Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes.
19 January 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual